SCP
VKTX icon

Sender Company & Partners’s Viking Therapeutics VKTX Stock Holding History

Sender Company & Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,136
Closed -$521K – 139
2026
Q1 		$525K Sell
16,136
-3,700
-19% -$119K 0.32% 36
2025
Q4 		$698K Buy
+19,836
New +$703K 0.33% 49

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Sender Company & Partners's VKTX Position: Q2 2026 in Review

Sender Company & Partners sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 16,136 shares — an estimated $521K sold.

Sender Company & Partners first reported a position in VKTX in Q4 2025 and held it in 2 quarters. The position peaked at $698K in Q4 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Sender Company & Partners reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Sender Company & Partners sold 16,136 Viking Therapeutics shares in Q2 2026, an estimated $521K.
  • Sender Company & Partners first reported a position in Viking Therapeutics in Q4 2025 and held it in 2 quarters.
  • Sender Company & Partners's Viking Therapeutics position peaked at $698K in Q4 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Sender Company & Partners's 13F filing for Q2 2026, filed 14 Aug 2026.